Homocysteine level is associated with aortic stiffness in elderly: cross-sectional results from the B-PROOF study

Suzanne C van Dijk1, Yvo M Smulders, Anke W Enneman

  • 1Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. s.c.vandijk@erasmusmc.nl

Insights

In older adults, elevated homocysteine levels are linked to increased aortic stiffness, a key factor in cardiovascular disease. This association is particularly strong in the oldest individuals, suggesting homocysteine

Area of Science:

  • Gerontology and Cardiovascular Health
  • Vascular Biology and Aging
  • Biomarkers of Cardiovascular Risk

Background:

  • Homocysteine is a recognized predictor of cardiovascular mortality, especially in the elderly.
  • Arterial stiffening is a critical pathophysiological process in cardiovascular disease development.
  • Understanding the link between homocysteine and arterial stiffening may elucidate cardiovascular risk in older populations.

Purpose of the Study:

  • To investigate the association between homocysteine levels and vascular function/structure in older adults.
  • To explore whether arterial stiffening mediates the relationship between homocysteine and cardiovascular risk in the elderly.

Main Methods:

  • Utilized cross-sectional data from the cardiovascular subgroup of the B-PROOF study (n=560, mean age ~73 years).
  • Assessed vascular parameters including aortic pulse wave velocity (aPWV), augmentation index (AIx), and aortic pulse pressure.
  • Employed linear regression and ANCOVA, adjusting for confounders like age, sex, renal function, and blood pressure.

Main Results:

  • A significant association was found between homocysteine and aortic pulse wave velocity (aPWV).
  • This association was age-dependent, being most pronounced in individuals aged 77-98 years.
  • No significant links were observed between homocysteine and AIx, carotid distensibility, carotid compliance, or aortic pulse pressure; the aPWV association was significant only in men.

Conclusions:

  • Homocysteine is associated with increased aortic stiffness in older individuals, particularly the oldest old.
  • Aortic stiffness may serve as a mediator for the heightened cardiovascular mortality risk associated with homocysteine in the elderly.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...